Quantcast
Channel: trial – THE "NEW" PROSTATE CANCER INFOLINK
Browsing latest articles
Browse All 110 View Live

LAST CHANCE to participate in our current survey

By late yesterday nearly 600 men had completed our recent survey and most of them had expressed some degree of interest in participating in the quality of life trial we will be initiating soon. Again,...

View Article



Prostvac in the treatment of prostate cancer: an update

As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial. A multinational, three-arm,...

View Article

Patient satisfaction at 24 months after treatment for localized prostate cancer

The ability to “manage” patients’ satisfaction with their care in the treatment of localized prostate cancer is challenging — for patients, for caregivers, for physicians, and for health systems. While...

View Article

J&J to seek approval of apalutamide in treatment of mCSPC

According to a media release issued yesterday by Johnson & Johnson, its Janssen Pharmaceuticals division has just submitted an application to the U.S. Food and Drug Administration for the approval...

View Article

UPDATE … the new PCa Social Network PLUS app

A couple of weeks ago (see here) we had first told you about the launch of the new PCa Social Network PLUS app that allows mobile access to a new social netowrk (and a clinical trial of its effects)...

View Article


Adjuvant chemotherapy does NOT improve BDFS rates in men with intermediate-...

With the third Advanced Prostate Cancer Consensus Conference (APCCC) due to start here in Basel, Switzerland, this morning, there is an important new set of data that will help to inform some of the...

View Article

High-dose vitamin D: negative results from a randomized clinical trial

Data from a recently published, Canadian, clinical trial of high-dose vitamin D as a method to strengthen bones in healthy adults who do not have osteoporesis have had significant and unexpectedly...

View Article

The first-line treatment of locally advanced prostate cancer (clinical stage T3)

Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy...

View Article


Sipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial

At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to...

View Article


Data from HERO trial reported — at virtual ASCO and in NEJM

The results of the Phase III HERO trial of relugolix — the first oral LHRH antagonist for treatment of advanced prostate cancer — have now been reported in the New England Journal of Medicine (NEJM)...

View Article

Ipatasertib meets one of two primary endpoints in Phase III trial

According to a media release issued by Roche earlier this morning, the company’s investigational drug known as ipatasertib met one but not both of the two primary endpoints in a randomized,...

View Article

Neoadjuvant CHT + surgery for men with high-risk, localized prostate cancer

Eastham et al. have recently reported — in the Journal of Clinical Oncology — results from a randomized Phase III trial of the surgical treatment of men with high-risk forms of localized prostate...

View Article

Onvansertib in treatment of abiraterone-resistant mCRPC

We hear that an investigational drug called onvansertib — a so-called polo-like kinase 1 (PLK1) inhibitor — may have benefit in the treatment of men with metastatic, castration-resistant prostate...

View Article


Early data from the PEACE-1 trial

The so-called PEACE-1 trial is an ongoing Phase III trial among men diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC). The earliest results of this trial are to be...

View Article

Major results of Phase III VISION trial announced

Earlier today, Novartis issued a media release giving the major results of the Phase III VISION trial, which compared the effectiveness of 177Lu-PSMA-617+ best standard of care (SOC), as selected by...

View Article

Browsing latest articles
Browse All 110 View Live




Latest Images